Avanir Pharma Publishes PBA Burden of Illness Study

Avanir Pharmaceuticals, Inc. AVNR announced today that Advances in Therapy published results from a U.S. survey conducted by Harris Interactive, comparing Quality of Life (QOL), Quality of Relationships (QOR), health status and daily function of neurologic patients with and without symptoms of pseudobulbar affect (PBA). A link to the online article can be accessed at http://www.advancesintherapy.com/. "The results from this survey demonstrate that PBA symptoms are associated with considerable burden incremental to that of the underlying neurological conditions, affecting quality of life and relationships, health status, and social and occupational functioning," said Randall Kaye, MD, chief medical officer at Avanir Pharmaceuticals. "This important information will help healthcare practitioners better appreciate and understand the multi-faceted impact of PBA symptoms on patients and their caregivers."
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!